12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring

Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring

Severe psychiatric illnesses, including Bipolar Disorder, Schizophrenia, and First-Episode Psychosis, require sophisticated psychopharmacological interventions and rigorous longitudinal laboratory safety monitoring. Pharmacists in Canadian hospital psychiatric units and primary care teams oversee complex mood stabilizer regimens, manage antipsychotic drug selection, mitigate adverse effects, coordinate clozapine registry requirements, and rapidly identify life-threatening medical emergencies such as Neuroleptic Malignant Syndrome (NMS).

---

CANMAT Bipolar Disorder Guidelines: Diagnostic Boundaries

Bipolar disorder is characterized by pathological shifts in mood, energy, and activity levels. The CANMAT clinical guidelines divide bipolar illness into distinct diagnostic subtypes with fundamentally different therapeutic regimens:

1. Bipolar I Disorder

• Defining Criterion: At least one lifetime manic episode.
• Diagnostic Threshold of Mania: A distinct period of abnormally and persistently elevated, expansive, or irritable mood, and persistently increased goal-directed activity or energy, lasting at least 1 week (7 days) (or any duration if hospitalization is required), accompanied by at least 3 symptoms (4 if mood is only irritable):
  • Grandiosity or inflated self-esteem;
  • Decreased need for sleep (e.g., feels fully rested after 2 hours);
  • Pressured, rapid speech;
  • Flight of ideas or subjective racing thoughts;
  • Extreme distractibility;
  • Psychomotor agitation or increased goal-directed activity;
  • Excessive involvement in activities with high potential for painful consequences (e.g., unrestrained shopping sprees, sexual indiscretions, reckless investments).
• Impairment: Causes marked impairment in social or occupational functioning, requires hospitalization, or exhibits psychotic features (delusions, hallucinations).
• Major depressive episodes frequently occur in Bipolar I but are not required for diagnosis.

2. Bipolar II Disorder

• Defining Criteria: At least one hypomanic episode AND at least one major depressive episode.
• Diagnostic Threshold of Hypomania: Same symptom checklist as mania, but lasting at least 4 consecutive days.
• Crucial Diagnostic Boundary: Hypomania produces a clear, observable change in functioning that is uncharacteristic of the individual, but it never causes marked social/occupational impairment, never requires hospitalization, and never involves psychotic features. If psychosis or hospitalization occurs, the episode is categorized as mania, reclassifying the patient as Bipolar I.

                           BIPOLAR I VS. BIPOLAR II CRITERIA

                   BIPOLAR I DISORDER                         BIPOLAR II DISORDER
    ┌──────────────────────────────────────────┐  ┌──────────────────────────────────────────┐
    │ • Requires ≥ 1 MANIC Episode             │  │ • Requires ≥ 1 HYPOMANIC Episode         │
    │ • Duration: ≥ 7 days (or hospitalized)   │  │ • Duration: ≥ 4 consecutive days         │
    │ • Marked functional impairment           │  │ • Observable change; NO marked impairment│
    │ • Psychotic symptoms may be present      │  │ • NEVER hospitalized; NEVER psychotic   │
    │ • Major depressive episodes common but   │  │ • MUST have ≥ 1 Major Depressive Episode │
    │   not strictly required for diagnosis    │  │   (causes the major burden of morbidity) │
    └──────────────────────────────────────────┘  └──────────────────────────────────────────┘

---

Evidence-Based Pharmacotherapy for Bipolar Disorder

CANMAT clinical guidelines establish clear treatment hierarchies for acute mania, acute bipolar depression, and long-term maintenance:

                          CANMAT BIPOLAR PHARMACOTHERAPY
                                         │
         ┌───────────────────────────────┴───────────────────────────────┐
         ▼                                                               ▼
   ACUTE MANIA (First-Line)                               BIPOLAR DEPRESSION (First-Line)
• Monotherapy:                                         • Quetiapine monotherapy (300 mg daily)
  - Lithium (target 0.8–1.2 mmol/L)                   • Lurasidone (20–120 mg) ± Lithium/Divalproex
  - Divalproex (target 350–700 µmol/L)                 • Lamotrigine (maintenance/depression prevention)
  - Atypical Antipsychotics: Quetiapine,               • (Lumateperone: US-approved; check Canadian status)
    Aripiprazole, Risperidone, Asenapine               • Lithium monotherapy
• Combination Therapy (Severe Mania):                  *ANTIDEPRESSANT MONOTHERAPY IS STRICTLY
  - Lithium or Divalproex + Atypical Antipsychotic      AVOIDED (HIGH RISK OF AFFECTIVE SWITCH)*

1. Acute Mania (First-Line Agents)

• First-Line Monotherapy: Lithium, Divalproex sodium, or an Atypical Antipsychotic (quetiapine, aripiprazole, risperidone, asenapine, paliperidone, cariprazine).
• Combination Regimens for Severe Mania: For severe acute mania presenting with marked agitation or psychosis, combination therapy (Lithium OR Divalproex PLUS an Atypical Antipsychotic) demonstrates significantly faster antimanic onset and superior response rates compared to monotherapy.

2. Acute Bipolar Depression (First-Line Agents)

Treating bipolar depression is notoriously challenging because conventional antidepressants are often ineffective or destabilizing. First-line agents supported by Level 1 CANMAT evidence include:

• Quetiapine monotherapy (300 mg daily at bedtime; binds 5-HT2A, D2, and its metabolite norquetiapine inhibits NET);
• Lurasidone (monotherapy or adjunctive to lithium or divalproex; must be taken with food [≥ 350 calories]);
• Lamotrigine (particularly effective in preventing depressive relapses);
• Lithium monotherapy.

3. Lamotrigine Dosing, Titration & SJS/TEN Safety Rules

Lamotrigine stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting glutamate release. It carries a Health Canada boxed warning for severe, life-threatening cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

• Slow Titration Protocol: To prevent SJS/TEN, lamotrigine must be escalated slowly: 25 mg daily for Weeks 1–2; 50 mg daily for Weeks 3–4; 100 mg daily for Week 5; target maintenance 200 mg daily.
• Crucial Drug Interactions:
  • Valproate Co-administration: Valproate inhibits lamotrigine glucuronidation (via UGT2B7), doubling lamotrigine serum concentrations and dramatically elevating SJS risk. When combining with valproate, cut the lamotrigine starting dose and titration schedule by 50% (i.e., 25 mg every other day for Weeks 1–2, then 25 mg daily for Weeks 3–4).
  • Enzyme Inducers (Carbamazepine, Phenytoin): Accelerate lamotrigine clearance; double the lamotrigine dose and titration rate.

---

Schizophrenia & Psychosis: Dopaminergic Neurocircuitry

Schizophrenia is a complex neuropsychiatric disorder characterized by positive symptoms (delusions, hallucinations, thought disorder), negative symptoms (flat affect, avolition, alogia, anhedonia), and cognitive deficits. Antipsychotic efficacy and adverse effects are directly mediated by dopamine D2 receptor blockade across four primary cerebral tracts:

                           CEREBRAL DOPAMINE PATHWAYS

      PATHWAY                 PHYSIOLOGICAL ROLE                   D2 ANTAGONISM CONSEQUENCE
┌──────────────────┬─────────────────────────────────────┬─────────────────────────────────────┐
│ 1. Mesolimbic    │ Motivation, reward, emotion         │ Reduces POSITIVE symptoms           │
│                  │ (Hyperactive in schizophrenia)      │ (Therapeutic target of all APs)     │
├──────────────────┼─────────────────────────────────────┼─────────────────────────────────────┤
│ 2. Mesocortical   │ Cognition, executive function, affect│ Can worsen NEGATIVE symptoms &      │
│                  │ (Hypoactive in schizophrenia)       │ neurocognitive blunting             │
├──────────────────┼─────────────────────────────────────┼─────────────────────────────────────┤
│ 3. Nigrostriatal │ Regulates motor execution via       │ Causes EXTRAPYRAMIDAL SYMPTOMS      │
│                  │ extrapyramidal system               │ (Dystonia, Akathisia, Parkinsonism, TD)│
├──────────────────┼─────────────────────────────────────┼─────────────────────────────────────┤
│ 4. Tubero-       │ Dopamine tonically inhibits         │ Causes HYPERPROLACTINEMIA           │
│    infundibular  │ prolactin release from pituitary    │ (Galactorrhea, amenorrhea, sexual fx)│
└──────────────────┴─────────────────────────────────────┴─────────────────────────────────────┘

---

First-Generation vs. Second-Generation Antipsychotics

Antipsychotics are divided into First-Generation (FGAs / typicals) and Second-Generation (SGAs / atypicals):

1. First-Generation Antipsychotics (FGAs)

• Agents: Haloperidol, Chlorpromazine, Fluphenazine, Loxapine, Zuclopenthixol.
• Pharmacology: Potent, high-affinity competitive antagonists of post-synaptic dopamine D2 receptors. Clinical antipsychotic response requires ~65% striatal D2 occupancy, but exceeding ~80% D2 occupancy sharply increases the risk of Extrapyramidal Symptoms (EPS) and hyperprolactinemia.
• EPS Spectrum and Clinical Management:
  • Acute Dystonia (Hours to Days): Severe, sustained, involuntary muscle contractions (torticollis [neck twisting], oculogyric crisis [upward eye deviation], trismus [jaw clenching], laryngeal spasm). Emergency Treatment: Immediate administration of an anticholinergic agent: Benztropine 1–2 mg IM/IV or Diphenhydramine 25–50 mg IM/IV, followed by oral anticholinergics for 3 to 7 days.
  • Akathisia (Days to Weeks): Subjective, intolerable inner restlessness and an irresistible motor urge to pace, rock, or shift feet. Often misdiagnosed as psychotic agitation. Treatment: First-line therapy is a lipophilic beta-blocker (Propranolol 10–40 mg BID/TID) or low-dose lorazepam; reduce antipsychotic dose or switch to an SGA with lower D2 affinity.
  • Pseudoparkinsonism (Weeks to Months): Bradykinesia, resting "pill-rolling" tremor, cogwheel rigidity, masked facies, and shuffling gait. Treatment: Reduce antipsychotic dose, switch to an SGA, or add oral benztropine.
  • Tardive Dyskinesia (TD) (Months to Years): Potentially irreversible choreoathetoid movements of the face, tongue (tongue protrusion, lip smacking), jaw, or extremities resulting from chronic D2 up-regulation. Management: Anticholinergics worsen TD! First reduce or stop the causative drug if possible, or switch to clozapine or quetiapine. Vesicular monoamine transporter 2 (VMAT2) inhibitors treat TD: valbenazine and deutetrabenazine are approved in the US, while tetrabenazine is the long-established VMAT2 inhibitor in Canada. Check current Canadian availability and coverage before recommending one.

2. Second-Generation Antipsychotics (SGAs)

• Agents: Olanzapine, Clozapine, Quetiapine, Risperidone, Paliperidone, Aripiprazole, Lurasidone, Ziprasidone, Brexpiprazole, Cariprazine.
• Pharmacology: Combined serotonin 5-HT2A and dopamine D2 antagonism. 5-HT2A blockade promotes local dopamine release in the nigrostriatal and tuberoinfundibular tracts, mitigating EPS and prolactin elevation. Aripiprazole and brexpiprazole act as partial D2 agonists, stabilizing dopaminergic tone without causing complete shutdown.

---

Metabolic Syndrome & SGA Monitoring Protocol

Second-generation antipsychotics carry significant risk of metabolic syndrome (weight gain, dyslipidemia, insulin resistance, type 2 diabetes mellitus, and accelerated atherosclerotic cardiovascular disease). The metabolic liability varies dramatically across agents:

• High Metabolic Risk: Clozapine and Olanzapine (induce severe weight gain [often > 10 kg], hypertriglyceridemia, and rapid-onset diabetic ketoacidosis);
• Moderate Metabolic Risk: Quetiapine, Risperidone, Paliperidone;
• Low Metabolic Risk / Weight Neutral: Aripiprazole, Lurasidone, Ziprasidone.

Canadian Standardized Metabolic Monitoring Schedule

The Canadian Psychiatric Association and Diabetes Canada establish the following monitoring protocol for all patients initiated on SGAs:

                      STANDARDIZED SGA METABOLIC MONITORING MATRIX

   PARAMETER                        BASELINE        1 MONTH      3 MONTHS       ANNUALLY
┌─────────────────────────────────┬──────────────┬────────────┬──────────────┬────────────┐
│ Personal / Family History       │     YES      │     —      │      —       │    YES     │
│ Weight / BMI / Waist Circ.      │     YES      │    YES     │     YES      │ Quarterly  │
│ Blood Pressure                  │     YES      │     —      │     YES      │    YES     │
│ Fasting Plasma Glucose / HbA1c  │     YES      │     —      │     YES      │    YES*    │
│ Fasting Lipid Profile (TG, LDL) │     YES      │     —      │     YES      │    YES     │
└─────────────────────────────────┴──────────────┴────────────┴──────────────┴────────────┘
   *Repeat fasting glucose at 6 months if significant weight gain (> 5% of body weight) occurs.

---

Clozapine: Gold Standard in Treatment-Resistant Schizophrenia

Clozapine is the single most effective antipsychotic in clinical medicine, with unique efficacy in Treatment-Resistant Schizophrenia (TRS) (defined as failure of at least two adequate trials of different antipsychotics at therapeutic doses for ≥ 6 weeks, at least one being an SGA) and in reducing recurrent suicidal behavior in schizophrenia.

Mandatory Health Canada Clozapine Registry & Hematological Monitoring

Clozapine carries a life-threatening risk of severe neutropenia and agranulocytosis (< 1% incidence, peak risk in first 18 weeks). Dispensing clozapine in Canada is legally contingent upon patient registration and regular reporting through a recognized manufacturer monitoring registry (e.g., CSAN, Clozaril Support, Gen-Clozapine).

• Mandatory Monitoring Frequency:
  • Weeks 1 to 26: WBC and ANC measured weekly;
  • Weeks 27 to 52: WBC and ANC measured every 2 weeks;
  • After 52 Weeks (Year 2+): WBC and ANC measured every 4 weeks for as long as clozapine continues.
• Action Thresholds (Canadian clozapine monographs and registries):

                  CLOZAPINE WBC/ANC ACTION THRESHOLDS (CANADIAN PRODUCT MONOGRAPH)

   START / CONTINUE (Green): WBC ≥ 3.5 × 10⁹/L AND ANC ≥ 2.0 × 10⁹/L
   ► Clozapine may be started only at or above these values.

   CAUTION (Yellow/Amber): WBC 2.0 to 3.5 × 10⁹/L OR ANC 1.5 to 2.0 × 10⁹/L
   ► Continue clozapine; increase blood counts to TWICE WEEKLY until values recover.
   ► Also twice weekly after a large fall within 4 weeks: WBC down ≥ 3.0 to below 4.0,
     or ANC down ≥ 1.5 to below 2.5 × 10⁹/L, or flu-like symptoms.

   STOP (Red): WBC < 2.0 × 10⁹/L OR ANC < 1.5 × 10⁹/L
   ► Stop clozapine immediately; check daily counts; watch for infection.
   ► The patient is registered as NON-RECHALLENGEABLE.

Other Life-Threatening Clozapine Toxicities

1. Fatal Gastrointestinal Hypomotility (Paralytic Ileus): Due to extreme anticholinergic (M3) and antiserotonergic actions. Mortality from clozapine-induced bowel necrosis and toxic megacolon equals or exceeds that of agranulocytosis. Clinical Rule: Routine prophylactic bowel regimens (e.g., Polyethylene glycol 3350) should be initiated; immediately investigate severe constipation, abdominal pain, or distension.
2. Myocarditis & Cardiomyopathy: Most common in the first 4 to 6 weeks. Screen for unexplained persistent tachycardia (resting HR > 100 bpm), chest pain, dyspnea, fever, or elevated troponin/CRP. If myocarditis is confirmed, permanently discontinue clozapine.
3. Dose-Dependent Seizures: Seizure threshold drops sharply at doses > 600 mg/day or with rapid upward titration. Manage by reducing dose, obtaining an EEG, and co-administering valproate (avoid carbamazepine due to synergistic bone marrow toxicity!).
4. Severe Sialorrhea (Hypersalivation): Mediated by muscarinic M4 receptor agonism and loss of the swallowing reflex during sleep. Treat with sublingual atropine 1% ophthalmic drops (1–2 drops under the tongue at bedtime) or ipratropium nasal spray applied orally.

---

Neuroleptic Malignant Syndrome (NMS)

Neuroleptic Malignant Syndrome (NMS) is an idiosyncratic, life-threatening medical emergency caused by profound central dopamine D2 receptor blockade, occurring in 0.02% to 0.2% of patients treated with antipsychotics.

The Diagnostic Clinical Tetrad

                           DIAGNOSTIC CLINICAL TETRAD OF NMS

   1. HYPERTHERMIA ──────────► Core temperature often exceeding 38°C to 40°C (extreme pyrexia)
   2. "LEAD-PIPE" RIGIDITY ──► Severe generalized skeletal muscle rigidity, cogwheeling
   3. AUTONOMIC DYSFUNCTION ─► Tachycardia, labile blood pressure, profuse diaphoresis, tachypnea
   4. ALTERED MENTAL STATUS ─► Confusion, delirium, catatonic mutism progressing to stupor/coma

Laboratory Hallmarks

• Marked Serum Creatine Kinase (CK) Elevation: Typically > 1,000 IU/L, frequently ranging between 10,000 and 100,000+ IU/L due to widespread skeletal muscle necrosis (rhabdomyolysis).
• Leukocytosis: WBC count markedly elevated (10 to 40 × 10^9/L).
• Acute Kidney Injury: Elevated BUN and serum creatinine resulting from myoglobin precipitation in renal tubules.
• Metabolic Acidosis & Transaminitis: Elevated serum lactate, AST, and ALT.

Step-by-Step Emergency Management Protocol

1. Immediate Cessation: Stop the offending antipsychotic agent immediately, along with any other antidopaminergic drugs (e.g., metoclopramide, prochlorperazine).
2. Aggressive ICU Supportive Care:
   • Intravenous crystalloid fluid resuscitation (200–300 mL/hr) to maintain vigorous urine output (> 100 mL/hr) and flush myoglobin to prevent acute tubular necrosis;
   • Active external cooling (cooling blankets, ice packs; standard antipyretics like acetaminophen are ineffective because hyperthermia is caused by continuous muscle rigidity);
   • Mechanical airway protection and hemodynamic stabilization.
3. Targeted Pharmacotherapy:
   • Dantrolene: Direct-acting skeletal muscle relaxant (inhibits ryanodine receptor calcium release from sarcoplasmic reticulum). Dose: 1 to 2.5 mg/kg IV bolus, repeated up to max 10 mg/kg/day.
   • Bromocriptine: Central dopamine D2 agonist. Dose: 2.5 to 5 mg PO/NG three times daily, titrated up to 15–20 mg/day to overcome central hypothalamic dopaminergic blockade.
   • Amantadine: Indirect dopamine agonist and NMDA antagonist.
4. Rechallenge Guidelines: If an antipsychotic is subsequently required, wait a minimum of 2 weeks after complete clinical recovery and CK normalization. Select a chemically distinct SGA with low D2 receptor affinity (e.g., quetiapine or clozapine) and titrate slowly from low subtherapeutic doses.

---

Clinical Decision-Making Scenario: Managing Treatment-Resistant Psychosis

A 27-year-old male with schizophrenia has failed successive 8-week trials of risperidone 6 mg daily and olanzapine 20 mg daily, with persistent auditory hallucinations, persecutory delusions, and social withdrawal. His metabolic workup shows a BMI of 32 kg/m² and fasting glucose of 6.2 mmol/L. The psychiatric team decides to initiate clozapine.

Pharmacist Clinical Assessment & Implementation Plan:

1. Verify Indication: The patient meets criteria for Treatment-Resistant Schizophrenia (failure of ≥ 2 antipsychotics of adequate dose and duration, including an SGA). Clozapine is the definitive gold standard.
2. Registry Enrollment & Baseline Blood Work: Ensure patient registration with the Health Canada authorized registry (CSAN). Baseline complete blood count shows a WBC of 5.6 × 10^9/L and an ANC of 2.4 × 10^9/L, both above the start thresholds (WBC ≥ 3.5, ANC ≥ 2.0), so clozapine may be initiated. Order baseline troponin, CRP, ECG, fasting glucose, lipids, and baseline bowel assessment.
3. Dosing Schedule: Start clozapine at 12.5 mg once or twice daily, titrating slowly by 25 to 50 mg/day to a target dose of 300 to 450 mg/day over 2 to 3 weeks to minimize severe orthostatic hypotension and seizure risks.
4. Proactive Bowel Care: Prescribe polyethylene glycol 3350 (17 g daily) prophylactically to prevent clozapine-induced gastrointestinal hypomotility and fatal ileus.
5. Longitudinal Monitoring: Schedule mandatory weekly CBC/ANC draws for the first 26 weeks.